Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 15/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | MARK3 | P27448 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427386 | 0.94 | CRHR1 (0.53) | CRHR1MCHR1PLK4CHEK1AURKA | |
| SCHEMBL5409765 | 0.81 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL5406538 | 0.81 | CRHR1 (0.40) | CRHR1PLK4CHEK1AURKANTRK1 | |
| SCHEMBL5421161 | 0.81 | CRHR1 (0.60) | CRHR1PLK4CHEK1AURKANTRK1 | |
| SCHEMBL5414425 | 0.79 | CRHR1 (0.58) | CRHR1 | |
| SCHEMBL5440212 | 0.78 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL5533898 | 0.77 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL7475280 | 0.76 | MCHR1 (0.39) | CRHR1MCHR1 | |
| SCHEMBL5535716 | 0.76 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL5535711 | 0.76 | CRHR1 (0.52) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1500653-A1 | Substituted arylpyrazines | Neurogen Corporation (US) | 2005-01-26 | — | — | EP | claimed |
| US-20030018035-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2003-01-23 | — | — | US | claimed |
| EP-1255740-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001060806-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-6995161-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050215559-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
| EP-1255740-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060806-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885MCHR1 57/4885PLK4 4236/4885 |
| US-20050215559-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885MCHR1 57/4885PLK4 4236/4885 |
| US-20030018035-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885MCHR1 51/4885PLK4 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.